 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Amid the global increase in the number of obese people, the demand for investment is believed to have driven as related markets are expected to grow.
According to the Korea Exchange on the 20th, Peptron surged 54% in the three days from the 17th to the 19th, ranking first in the domestic stock market. Stock prices jumped 26% on the 18th, and rose to the upper limit on the 19th. Stock prices also rose 3.8 percent on the 20th. According to stock price trends since early this year, Pepsin's stock price growth rate has reached 246%.
Shares of iSense, which produces blood glucose meters, also rose 45% over the past four days from the 17th. During this period, I-Sense's stock price growth rate is the third overall. The stock price, which stood at 7,600 won at the end of last year, is now above 26,000 won. What these companies have in common is that they have related technologies such as diabetes measurement and treatment. As the obese population increases worldwide, stock prices of companies with diabetes-related technologies, a major complication of obesity, appear to have been affected as countries are agonizing over solutions.
The World Health Organization (WHO) is expected to consider adding obesity drugs to the list of essential medicines.
This means that the market for obesity and diabetes treatment is likely to continue to grow. Investment bank Morgan Stanley predicted that the obesity treatment market, which was $ 2.4 billion last year, will surge to $ 54 billion (about KRW 71.226 trillion) in 2030.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
